Thermo Fisher opens new viral vector manufacturing facility
The new facility in Plainville, Massachusetts is intended to manufacture materials central to the production of gene-based therapeutics
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 Aug 22
The new facility in Plainville, Massachusetts is intended to manufacture materials central to the production of gene-based therapeutics
24 Aug 22
In the updated analysis, the Pfizer-BioNTech Covid-19 vaccine showed 73.2% efficacy in children aged six months to four…
24 Aug 22
MK-2060 is a monoclonal antibody under development which is intended to block Factor XI's capacity to activate downstream…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 Aug 22
Clinical nutrition market from parenteral nutrition segment held more than 11% share in 2021 and is projected to…
23 Aug 22
In addition to the joint development projects, Zerion has granted Hovione an exclusive license to exploit the Dispersome®…
23 Aug 22
The EC authorisation for Sunlenca is said to provide a new, every six-month treatment option for people with…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 Aug 22
Both companies have scaled production to deliver doses of Omicron BA.4/BA.5-adapted bivalent vaccinations and shipping after authorisation
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Aug 22
Auvelity is the first and only rapid-acting oral drug approved for MDD, with a significant antidepressant efficacy compared…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Aug 22
Crysvita is said to be the first biologic therapy authorised in the EU for TIO patients who cannot…
19 Aug 22
Vegzelma is said to provide a new, safe, and effective treatment option for Europeans living with certain types…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates